Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you provide anthracycline-based therapy for early stage node negative triple-negative breast cancer in patient with echocardiogram showing grade 1 diastolic dysfunction?
Is there an indication for dexrazoxane?
Related Questions
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
How do you treat ER/PR + DCIS with no identified invasive component that has microscopic sentinel lymph node metastasis? Would you complete HER2 staining on original specimen?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
Would you discontinue tamoxifen for endometrial hyperplasia without dysplasia in the adjuvant setting?
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?